Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)

Dr. Paul R. Conkling

Hematology | Oncology
Virginia Oncology Associates
1051 Loftis Blvd, Suite 100, 
Newport News, VA 
Accepting New Patients
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Virginia Oncology Associates
1051 Loftis Blvd, Suite 100, 
Newport News, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Conkling is a Hematologist and an Oncologist in Newport News, Virginia. Dr. Conkling is rated as an Advanced provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Anal Cancer. Dr. Conkling is currently accepting new patients.

His clinical research consists of co-authoring 31 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Specialist in VA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Optima Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

VIRGINIA ONCOLOGY ASSOCIATES
1051 Loftis Blvd, Suite 100, Newport News, VA 23606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drugs: LY3484356, Abemaciclib, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor
Study Phase: Phase 1
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 9 Less Clinical Trials

31 Total Publications

Erratum: Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Erratum: Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States.
Journal: JCO clinical cancer informatics
Published: March 05, 2025
Similar Doctors
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Edward B. Perkins
Oncology | Hematology
Distinguished in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Edward B. Perkins
Oncology | Hematology
1250 E Marshall St, 
Richmond, VA 
 (60.7 miles away)
804-828-9723
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edward Perkins is an Oncologist and a Hematologist in Richmond, Virginia. Dr. Perkins is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Childhood Acute Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Perkins is currently accepting new patients.

Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Burton F. Alexander
Hematology | Oncology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Burton F. Alexander
Hematology | Oncology

Virginia Oncology Associates

6251 E Virginia Beach Blvd, Suite 200, 
Norfolk, VA 
 (22.7 miles away)
757-466-8683
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Burton Alexander is a Hematologist and an Oncologist in Norfolk, Virginia. Dr. Alexander is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Anemia, Pulmonary Embolism, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome. Dr. Alexander is currently accepting new patients.

Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Valiant D. Tan
Hematology | Oncology
Advanced in Diffuse Large B-Cell Lymphoma (DLBCL)
Dr. Valiant D. Tan
Hematology | Oncology

Virginia Oncology Associates

744 Battlefield Blvd N, Suite 200, 
Chesapeake, VA 
 (26.8 miles away)
757-549-4403
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients
Offers Telehealth

Valiant Tan is a Hematologist and an Oncologist in Chesapeake, Virginia. Dr. Tan is rated as a Distinguished provider by MediFind in the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). His top areas of expertise are Thrombocytopenia, Familial Colorectal Cancer, Paget Disease of the Breast, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Tan is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Conkling's expertise for a condition
ConditionClose
    View All 28 Advanced Conditions
    View All 89 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile